This CtIP function is even more important in cells with diminished fork protection due to BRCA1 defects, suggesting CtIP as a novel therapeutic target to augment genotoxic cancer therapy of tumors with BRCA1 defects [140]. This evidence concerns the gene BRCA1 and cancer.